Nurullah İlhan, Associate Professor of Medical Oncology at Sancaktepe Şehit Prof. Dr. İlhan Varank Training and Research Hospital, shared key takeaways on X regarding two significant breast cancer studies presented at ESMO 2026:
“DESTINY-Breast09
In 61 patients with baseline brain metastases, CNS-PFS HR was 0.26 for T-DXd + pertuzumab vs THP; CNS response 51.6% vs 26.7%. Exploratory analysis in inactive/stable BMs. Impact on 1L choice?
OptiTROP-Breast01
In previously treated mTNBC, sac-TMT sustained its OS benefit vs chemotherapy: median OS 14.7 vs 9.9 months (HR 0.60); 30-month OS 26.8% vs 13.2%. Where will this ADC fit in sequencing?”
Find out more:
